Allergan partners with Mimetogen to advance development of dry eye treatment
Allergan has entered into a $50 million licensing deal to develop and commercialize tavilermide (MIM-D3), Mimetogen Pharmaceutical's lead product for the treatment of dry eye syndrome (DES). Read More »